(R)-2,2,2-Trifluoro-1-(4-chloro-phenyl)-ethylamine hydrochloride, 97%, 250mg

trans-4-Ethylcyclohexanol>96.0%(GC)1g

5-Fluoro-2-methoxypyridine-4-boronic acid, 98.0%, 25g

5-Chloro-2-hydroxynicotinic Acid>98.0%(T)1g

1-Benzyl-5-nitro-1H-imidazole-4-carboxylic acid, 95.0%, 10g

(1R,8S,9s)-Bicyclo[6.1.0]non-4-yn-9-ylmethyl succinimidyl carbonate, ?97.0%, 50mg

GC capillary column ROTI®Cap-5, 60 m, 0.32 mm, 0.50 µm, 1 Piece(s)

Rotigotine>98.0%(HPLC)(T)10mg

(R)-N-(1-(7-(But-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)-2,2,2-trifluoroacetamide (Linagliptin Impurity), 97%, 50mg

Quinazolin-8-ol, 95.0%, 250mg

1-(2-BROMOETHOXY)-3-FLUOROBENZENE, 95.0%, 2g

(S)-tert-Butyl 2-(2-hydroxyethyl)azetidine-1-carboxylate, 98%, 250mg

5-BROMO-3-(TRIFLUOROACETYL)INDOLE, 95.0%, 10g